Ranvu · DIN 02568950 · 10 mg/mL · injection, 0.165 mL pre-filled syringe (preservative-free)
Limited Use, Reason for Use code 651, 652, 653, 654 requiredApproved · checked October 5, 2026
StatusLimited Use, Reason for Use code 651, 652, 653, 654 required
Write on scriptone applicable Reason for Use code, 651 or 652 or 653 or 654 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 651, 652, 653, 654
Reason for Use code 651
For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye.
Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.
Patients receiving concurrent administration with another anti-VEGF agent are not eligible for reimbursement.
Treatment should be initiated with a loading phase of one injection per month for three consecutive months, followed by a maintenance phase.
During the maintenance phase, patients should be monitored for best corrected visual acuity or continued disease activity. If there is clinical or diagnostic evidence of disease activity such as a loss of greater than 5 letters in visual acuity (Early Treatment Diabetic Retinopathy Score (ETDRS) chart or one Snellen line equivalent), ranibizumab may be administered.
The interval between two doses should not be shorter than one month.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 652
For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 11 percent.
Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity.
Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to DME and continued until stable visual acuity is reached again for three consecutive monthly assessments.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 653
For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity.
Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to macular edema secondary to retinal vein occlusion and continued until stable visual acuity is reached again for three consecutive monthly assessments.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 654
For the treatment of patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia.
Treatment is initiated with a single intravitreal injection. Monitoring is recommended monthly for the first 2 months and at least every 3 months thereafter during the first year. If monitoring reveals signs of disease activity (e.g. reduced visual acuity and/or signs of lesion activity), further treatment is recommended at a frequency of 1 injection per month until no disease activity is seen.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Ranvu · DIN 02568950
Manufacturer: Apotex Inc.; listing date 2026-09-29
Health Canada: Approved since 2026-06-10 · brand RANVU · ATC S01LA04 RANIBIZUMAB · form Solution · route Intravitreal · ingredients RANIBIZUMAB 10 MG/ML · company Apotex inc · schedule Prescription, Schedule d
Ranvu: Formulary list price $900.00 per unit (the source does not state the unit; exact figure $900.0000). What the ministry pays, not the patient.
Ministry pays: $900.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02568950)
Source record
DIN 02568950: Ranvu
Raw flags: sec12=Y, sec3=Y
Item: 920000833; group id 952; item number 2259; lccId 00372; manufacturer id APX
Source form: Inj Sol-0.165mL Pref Syr (Preservative-Free); strength: 10mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $900.0000; ministry $900.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02568950
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107122
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02568950
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since June 10, 2026 — choose a marketed DIN from the same-category list.